Response to DDAVP In mild Hemophilia A patients, in Search for dEterminants - RISE

Academisch Medisch Centrum0 个研究点目标入组 281 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Moderate/mild hemophilia: defined as a FVIII deficiency with a FVIII:C plasma concentration of 2-40 IU/DL.
•Treated or tested with DDAVP (between 1980 and 2013), and documented FVIII and VWF plasma levels prior to DDAVP administration and at least for 1 time point after DDAVP administration.

•Severe hemophilia A patients (factor VIII <1 IU/DL ) will be excluded from the study population.
•The patient has other bleeding disorders, especially von Willebrand Disease (documented vWF plasma levels are available)
•Type 2N von Willebrand Disease, or highly likely that patient has this disease since there are female bleeding patients in the pedigree
•First DDAVP test is not taken at current hemophilia treatment center

发起方